HC Wainwright reiterated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research report sent to ...

HC Wainwright reaffirmed their buy rating on shares of Endeavour Silver (NYSE:EXK – Free Report) (TSE:EDR) in a research ...

CleanSpark Inc (NASDAQ:CLSK) shares are trading lower Tuesday on the heels of the company’s fourth-quarter financial results.

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...

Although it has lowered in recent days, commentators were mostly positive, with one hold and four buy recommendations on the stock. The consensus rating for the stock, as classified by MarketBeat, is ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Fintel reports that on November 6, 2024, HC Wainwright & Co. initiated coverage of BitFuFu (NasdaqCM:FUFU) with a Buy recommendation. There are 9 funds or institutions reporting positions in BitFuFu.

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.

Reiterates HC Wainwright & Co.: Neutral to Neutral 11/11/2024 Maintains HC Wainwright & Co.: Neutral to Neutral 8/12/2024 Reiterates HC Wainwright & Co.: Neutral to Neutral 6/17/2024 Maintains HC ...